AB-101 clinical trials
Also written AB-101.
How each study uses AB-101 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the AB-101 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- AB-101
- 7
Studies by the year they started
7 studies that test it; most in 2023 (2)
| Year | Studies |
|---|---|
| 2018 | 1 |
| 2021 | 1 |
| 2023 | 2 |
| 2024 | 2 |
| 2025 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 6 · Other 1
Artiva Biotherapeutics, Inc. (2) · Arbutus Biopharma Corporation (1) · Applied Biology, Inc. (1) · Alphyn Biologics (1) · IRIS Research and Development, LLC (1) · Affimed GmbH (1)
Often tested with
Tested in the same studies.
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 2
Studies that test AB-101.
- Jul 2027Open-label Single-Center Study to Evaluate the Safety and Efficacy of Combining Rituximab and AB-101 in B-cell Associated Autoimmune Diseases.Phase 1 · IRIS Research and Development, LLC
- Aug 2027AB-101 in Combination With B-Cell Depleting mAb in Patients Who Failed Treatment for Class III or IV Lupus Nephritis or Other Forms of Refractory Systemic Lupus ErythematosusPhase 1 · Artiva Biotherapeutics, Inc.
Studies
Open first, then newest update. How each study uses AB-101 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 7
- Phase 2 Randomized Double-blind Study to Assess Topical Zabalafin Hydrogel Vs Vehicle in Mild to Moderate AD.RecruitingPhase 2Alphyn BiologicsNCT06855745Written as zabalafin
- Open-label Single-Center Study to Evaluate the Safety and Efficacy of Combining Rituximab and AB-101 in B-cell Associated Autoimmune Diseases.RecruitingPhase 1IRIS Research and Development, LLCNCT06581562Written as AB-101
- Safety, Tolerability, PK & PD of AB-101 Following Oral Administration in Healthy and CHB Subjects.CompletedPhase 1Arbutus Biopharma CorporationNCT05960240Written as AB-101
- AB-101 as Monotherapy and With Immunotherapy in Patients With Relapsed/Refractory B-Cell Non-Hodgkin LymphomaCompletedPhase 1/2Artiva Biotherapeutics, Inc.NCT04673617Written as AB-101
- AB-101 in Combination With B-Cell Depleting mAb in Patients Who Failed Treatment for Class III or IV Lupus Nephritis or Other Forms of Refractory Systemic Lupus ErythematosusActive, not recruitingPhase 1Artiva Biotherapeutics, Inc.NCT06265220Written as AB-101
- Phase 2 Study of AFM13 in Combination With AB-101 in Subjects With R/R HL and CD30+ PTCLTerminatedPhase 2Affimed GmbHNCT05883449Written as AB-101
- Study to Investigate the Effect of AB-101 in Breast Cancer SurvivorsCompletedEarly Phase 1Applied Biology, Inc.NCT03592121Written as AB-101